Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetyltryptophan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE known ✓ | P12821 | 3/20 | 0.57 |
| ▸ | TACR1 | P25103 | 6/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 2/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | BCL2A1 | Q16548 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.57 |
| ▸ | APEX1 | P27695 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetyltryptophan SCHEMBL181484 | 1.00 | TACR1 (0.64) | TACR1ALOX15POLBGAAKMT2A | |
| Acetyltryptophan SCHEMBL26911615 | 0.97 | TACR1 (0.64) | TACR1ALOX15POLBGAAKMT2A | |
| Acetyltryptophan SCHEMBL1205188 | 0.97 | TACR1 (0.64) | TACR1ALOX15POLBGAAKMT2A | |
| Acetyltryptophan SCHEMBL11481713 | 0.97 | TACR1 (0.64) | TACR1ALOX15POLBGAAKMT2A | |
| Acetyltryptophan SCHEMBL1304486 | 0.97 | TACR1 (0.64) | TACR1ALOX15POLBGAAKMT2A | |
| Acetyltryptophan SCHEMBL11472611 | 0.97 | TACR1 (0.64) | TACR1ALOX15POLBGAAKMT2A | |
| Acetyltryptophan SCHEMBL11471932 | 0.97 | TACR1 (0.64) | TACR1ALOX15POLBGAAKMT2A | |
| Acetyltryptophan SCHEMBL11472608 | 0.97 | TACR1 (0.64) | TACR1ALOX15POLBGAAKMT2A | |
| Acetyltryptophan SCHEMBL20422818 | 0.91 | KMT2A (0.68) | TACR1ALOX15POLBGAAKMT2A | |
| SCHEMBL13176572 | 0.88 | TACR1 (0.67) | TACR1ALOX15POLBKMT2AACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 592 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025126144-A1 | METHODS OF MONITORING PARAMETERS IN SOLUTION | CSL BEHRING AG (CH) | 2025-06-19 | — | — | WO | claimed |
| EP-4384215-A1 | DRY POWDER COMPOSITIONS OF OIL-IN-WATER (O/W) EMULSION ADJUVANTED VACCINES | Board of Regents, The University of Texas System (US) | 2024-06-19 | — | — | EP | claimed |
| US-20240189272-A1 | FORMULATIONS AND COMPOSITIONS OF DOCETAXEL | ZHUHAI BEIHAI BIOTECH CO., LTD. (CN) | 2024-06-13 | — | — | US | claimed |
| US-11918646-B2 | Dry adjuvanted immune stimulating compositions and use thereof for mucosal administration | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-03-05 | — | — | US | claimed |
| WO-2024026463-A1 | COMPOSITION FOR NASAL DELIVERY OF AN ACTIVE COMPOUND | HAPPY HEALING INC. (US) | 2024-02-01 | — | — | WO | claimed |
| WO-2023019194-A9 | DRY POWDER COMPOSITIONS OF OIL-IN-WATER (O/W) EMULSION ADJUVANTED VACCINES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-09-14 | — | — | WO | claimed |
| US-20230115214-A1 | DRY POWDER COMPOSITIONS OF OIL-IN-WATER (O/W) EMULSION ADJUVANTED VACCINES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-04-13 | — | — | US | claimed |
| WO-2023044277-A1 | SMAD7 POLYPEPTIDE FORMULATIONS | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2023-03-23 | — | — | WO | claimed |
| US-20230060631-A1 | DRY LIPOSOME ADJUVANT-CONTAINING VACCINES AND RELATED METHODS THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-03-02 | — | — | US | claimed |
| US-20230057155-A1 | DRY LIPOSOME FORMULATIONS AND RELATED METHODS THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-02-23 | — | — | US | claimed |
| WO-2014186754-A9 | DRY SOLID ALUMINUM ADJUVANT-CONTAINING VACCINES AND RELATED METHODS THEREOF | BOARD OF REGENTS THE UNIVERSITY OF TEXAS SYSTEM (US) | 2015-04-16 | — | — | WO | claimed |
| WO-2014186754-A2 | DRY SOLID ALUMINUM ADJUVANT-CONTAINING VACCINES AND RELATED METHODS THEREOF | BOARD OF REGENTS THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-11-20 | — | — | WO | claimed |
| WO-2014121210-A1 | METHODS FOR PRODUCING DIKETOPIPERAZINES AND COMPOSITIONS CONTAINING DIKETOPIPERAZINES | AMPIO PHARMACEUTICALS, INC. (US) | 2014-08-07 | — | — | WO | claimed |
| US-20110045065-A1 | SUBSTANCE HAVING ANTIOXIDANT, GEROPROTECTIVE AND ANTI-ISCHEMIC ACTIVITY AND METHOD FOR THE PREPARATION THEREOF | MARVEL LIFE SCIENCES LTD. (GB) | 2011-02-24 | — | — | US | claimed |
| EP-2265252-A2 | OPHTHALMIC PREPARATION CONTAINING A PYRIDINOL DERIVATE | Marvel Lifesciences Limited (GB) | 2010-12-29 | — | — | EP | claimed |
| WO-2009116076-A2 | STERILE OPTHALMIC PREPARATIONS AND A PROCESS FOR PREPARATION THEREOF | M. J. BIOPHARM PVT.LTD. (IN) | 2009-09-24 | — | — | WO | claimed |
| WO-2007041285-A2 | COMPLEXES OF INACTIVATED PEPSIN FRACTION AND HEAT SHOCK PROTEIN | VIRAL GENETICS, INC. (US) | 2007-04-12 | — | — | WO | claimed |
| US-5118794-A | Polyether surfactant to protect against heat denaturing | INSTITUT MERIEUX (FR) | 1992-06-02 | — | — | US | claimed |
| US-4727059-A | FREE FROM HEPATITIS VIRULENCE | SEROTHERAPEUTISCHES INSTITUT WIEN GESELLSCHAFT M.B.H. (AT) | 1988-02-23 | — | — | US | claimed |
| US-4391801-A | Plasma protein fraction substantially free of acetate ions | CUTTER LABORATORIES, INC. (US) | 1983-07-05 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110045065-A1 | SUBSTANCE HAVING ANTIOXIDANT, GEROPROTECTIVE AND ANTI-ISCHEMIC ACTIVITY AND METHOD FOR THE PREPARATION THEREOF | GPX4, PGC, GSR | ACE 853/4885TACR1 2727/4885ALOX15 254/4885 |
| US-20240189272-A1 | FORMULATIONS AND COMPOSITIONS OF DOCETAXEL | ALB, S100P, S100A11 | ACE 2397/4885TACR1 1650/4885ALOX15 3878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.